- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05462379
Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
March 25, 2024 updated by: MARILIA ALBANEZI BERTOLAZZI
Autologous Heterotopic Fresh Ovarian Graft in Young Woman With Locally Advanced Cervical Cancer Eligible for Pelvic Radiotherapy Treatment
Pelvic chemoradiotherapy (CRT) is an effective treatment for Locally Advanced Cervical Cancer (LACC).
However, CRT induces premature ovarian failure ceasing the production of ovarian hormones.
This may lead to severe consequences to the patient's life quality, sexuality and overall healthy.
An acceptable treatment to minimize the adverse effects caused by the lack of ovarian hormones is hormonal replacement but less than 40% of the patients younger than 50 years have access to this treatment.
A second alternative treatment is ovarian transposing which is a surgical technique with variable success rate depending on how far the ovaries are from the radiotherapy field.
A third, more promising, alternative is involves using autologous ovarian tissue as a graft in tissues far from the radiotherapy field.
This treatment has the potential of maintaining the natural ovarian hormones production at a lower-cost and requiring a simpler procedure.
The primary objective of this randomized phase 1-2 clinical trial is to validate the feasibility of ovarian tissue engraft into fatty tissue and its endocrine functionality.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marilia Bertolazzi, MD
- Phone Number: 5519989172189
- Email: marilia.bertolazzi@hc.fm.usp.br
Study Contact Backup
- Name: Jesus Carvalho
- Email: jesus.carvalho@hc.fm.usp.br
Study Locations
-
-
-
São Paulo, Brazil, 01246-000
- Recruiting
- Instituto do Cancer do Estado de Sao Paulo
-
Contact:
- Elaine Longo
- Phone Number: 55 11 38932632
- Email: elaine.longo@hc.fm.usp.br
-
Contact:
- Marilia Bertolazzi, PHD
- Phone Number: 5519989172189
- Email: marilia.bertolazzi@hc.fm.usp.br
-
Principal Investigator:
- Jesus Carvalho, PHD
-
Sub-Investigator:
- Marilia Bertolazzi, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pathologic diagnosis of squamous cell carcinoma or adenocarcinoma of the cervix.
- FIGO 2018 staging IB3 to IVA.
- Absence of ovarian involvement.
- Age ≤35 Years.
- Absence of metastatic disease.
- Written consent.
Exclusion Criteria:
- Previous treatment for cervical cancer or other malignant diseases.
- Rare histology tumors.
- Absence of one or both ovaries.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard treatment
10 patients: Pelvic Chemoradiotherapy
|
|
Experimental: Ovarian Graft
10 patients: Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy.
Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight.
One representative fragment will undergo histologic evaluation.
These procedures will be done in the same surgical time.
|
Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy.
Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight.
One representative fragment will undergo histologic evaluation.
These procedures will be done in the same surgical time.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosage of serum levels of follicle stimulating hormone (FSH) in mUI/ml in intervention (engraft of ovarian tissue into fatty tissue) and control groups. Dosage will be performed at baseline and post radiotherapy (2, 6, 12 and 24 months).
Time Frame: 2 years
|
Endocrine functionality is defined as FSH levels under 25 mUI/ml.
|
2 years
|
Dosage of serum levels of estradiol in pg/ml in intervention (engraft of ovarian tissue into fatty tissue) and control groups. . Dosage will be performed at baseline and post radiotherapy (2, 6, 12 and 24 months).
Time Frame: 2 years
|
Endocrine functionality is defined as estradiol upper 47 pg/mL.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosage of serum levels of glucose in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24).
Time Frame: 2 years
|
Evaluation of glucose metabolism.
|
2 years
|
Measure of serum glycated hemoglobin in percentage in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24).
Time Frame: 2 years
|
Evaluation of glucose metabolism.
|
2 years
|
Measure of serum levels of cholesterol in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24).
Time Frame: 2 years
|
Evaluation of lipid metabolism.
|
2 years
|
Measure of serum levels of triglycerides in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24).
Time Frame: 2 years
|
Evaluation of lipid metabolism.
|
2 years
|
Evaluate the changes in bone mineral density (BMD) in femoral neck and lumbar spine by bone densitometry, evaluating T and Z scores standard deviation (SD) in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24.
Time Frame: 2 years
|
2 years
|
|
Bioimpedance monitoring to evaluate changes in body composition by fat and lean mass percentage in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24).
Time Frame: 2 years
|
2 years
|
|
Quantification of body mass index reported in kg/m2 in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24).
Time Frame: 2 years
|
Evaluation of changes in body mass.
|
2 years
|
Score life quality in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) in intervention and control groups.
Time Frame: 2 years
|
EORTC QLQ C30 was developed and validated to assess the quality of life of cancer patients. The 30-item EORTC QLQ-C30 is a disease-specific measure that assesses multiple QoL domains in patients with cancer. There are five functioning scales that measure physical, role, emotional, cognitive, and social functioning. Three symptom scales measure fatigue, pain, and nausea/vomiting. |
2 years
|
Score life quality in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Cervical Cancer Module (EORTC QLQ C30 CX24) in intervention and control groups.
Time Frame: 2 years
|
EORTC QLQ-CX24 Scoring Manual The Cervical Cancer Module is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30.
The EORTC QLQ-CX24 was designed to assess disease-specific and treatment-specific aspects of QoL in patients with cervical cancer.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2022
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
June 8, 2024
Study Registration Dates
First Submitted
June 9, 2022
First Submitted That Met QC Criteria
July 13, 2022
First Posted (Actual)
July 18, 2022
Study Record Updates
Last Update Posted (Actual)
March 26, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP1782
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Cervical Carcinoma
-
Assiut UniversityNot yet recruitingLocally Advanced Cervical Carcinoma
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
AkesoRecruitingLocally Advanced Cervical CarcinomaChina
-
University of Santo Tomas Hospital, PhilippinesPhilippine Council for Health Research & DevelopmentNot yet recruitingLocally Advanced Cervical Carcinoma
-
Emory UniversityAstex Pharmaceuticals, Inc.RecruitingHead and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...United States
-
Memorial Sloan Kettering Cancer CenterRecruitingSkin Cancer | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the SkinUnited States
-
Shanghai Runshi Pharmaceutical Technology Co., LtdJilin Provincial Tumor HospitalRecruitingLocally Advanced Unresectable CarcinomaChina
-
Mayo ClinicRecruitingMetastatic Lung Non-Small Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Resectable Lung Non-Small Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Metastatic Bladder Urothelial Carcinoma | Metastatic Colorectal Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Locally... and other conditionsUnited States
-
M.D. Anderson Cancer CenterCompletedAdenocarcinoma | Cervical Cancer | Cervical Squamous Cell Carcinoma | Locally Advanced Malignant Neoplasm | Adenosquamous CarcinomaUnited States, Belgium
Clinical Trials on Ovarian graft
-
Assistance Publique - Hôpitaux de ParisAgence de La BiomédecineUnknownOvarian Tissue TransplantationFrance
-
Shandong Provincial HospitalShandong UniversityCompleted
-
Kaohsiung Veterans General Hospital.CompletedFertilization in VitroTaiwan
-
Hadassah Medical OrganizationUnknown
-
Shandong Provincial HospitalShandong UniversityCompleted
-
Shen-Zhen City Maternity and Child Healthcare HospitalCompletedPolycystic Ovary Syndrome | Infertility | Anovulation
-
Shaimaa Mostafa Mohammed Refaay El shemyCompletedOvarian EndometriomaEgypt
-
Saad AmerUniversity Hospitals of Derby and Burton NHS Foundation TrustUnknown
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause | Amenorrhea | Infertility, Female | Anovulatory InfertilityGreece
-
Hacettepe UniversityRecruitingActivation of Primordial FolliclesTurkey